Navigation Links
Conseco to Implement Systems and Operational Solution From Long Term Care Group
Date:11/28/2007

ility to remediate the material weakness in internal controls over the actuarial reporting process that we identified at year-end 2006 and to maintain effective controls over financial reporting; (ix) our ability to continue to recruit and retain productive agents and distribution partners and customer response to new products, distribution channels and marketing initiatives; (x) our ability to achieve an upgrade of the financial strength ratings of our insurance company subsidiaries as well as the potential impact of rating downgrades on our business; (xi) the risk factors or uncertainties listed from time to time in our filings with the Securities and Exchange Commission; (xii) regulatory changes or actions, including those relating to regulation of the financial affairs of our insurance companies, such as the payment of dividends to us, regulation of financial services affecting (among other things) bank sales and underwriting of insurance products, regulation of the sale, underwriting and pricing of products, and health care regulation affecting health insurance products; (xiii) general economic conditions and other factors, including prevailing interest rate levels, stock and credit market performance and health care inflation, which may affect (among other things) our ability to sell products and access capital on acceptable terms, the returns on and the market value of our investments, and the lapse rate and profitability of policies; and (xiv) changes in the Federal income tax laws and regulations which may affect or eliminate the relative tax advantages of some of our products.

Other factors and assumptions not identified above are also relevant to the forward-looking statements, and if they prove incorrect, could also cause actual results to differ materially from those projected. All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by the foregoing cautionary statement. Our forward-looking stat
'/>"/>

SOURCE Conseco, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Conseco to Host Follow-Up Long-Term Care Conference Call
2. Barta joins Conseco as Senior Vice President, Financial Planning & Analysis; Barra named Senior Vice President, Internal Audit; Clarke to head Investor Relations
3. Conseco Completes Divestiture of Old Block of Fixed and Equity-Indexed Annuities
4. Conseco Sets Earnings Release Date
5. Conseco Reports Third Quarter Results
6. Keane Wins $1 Million Electronic Medical Record (EMR) Implementation at New Jersey-Based Acute Care Facility
7. Additional Top Tier Institutions Implement Mediwares HCLL(TM) Transfusion Management Software
8. Delmarva Foundation Implements Medication Therapy Management Program in Maryland and DC
9. Newton-Wellesley Hospital First in Massachusetts to Implement Isabel Diagnosis Decision Support System
10. AHIMA Signs Contract With CMS for ICD-10 Implementation Assessment and Training
11. Wild American Shrimp Board Agrees To Implement New Self-Funding Measures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)...c. 4 Aurora Health Care is ramping...upplements. Aurora,s Care Management,Clinical Lea...e all Aurora,caregivers about the benefits of Vit...idence that higher Vitamin D levels may improve ou...sis, certain muscle conditions and,seasonal depre...
(Date:12/4/2008)...as, Dec. 4 MiddleBrook,...ounced that it has opened its,administrative and ...rmantown,facility will continue to house certain ...research and development group. The newly leased ...to house up to 60 employees as MiddleBrook,grows....
(Date:12/4/2008)...ch., Dec. 4 BAPTIST HEALTH, a six-...he state,s largest health system, has,expanded it... Reuters -- a,solution that enabled the system,s ...entions and save more than $1 million. , "D... campus show that,CareFocus prompts approximately...
(Date:12/4/2008)...similar to those seen with standard dose of daunor... (HealthDay News) -- A high dose of the chemothera...ts with previously untreated acute myeloid leukemi...by the U.S. National Cancer Institute (NCI) show. ... This study included 633 patients, aged 16 to 60, ...
Breaking Medicine News(10 mins):Health News:Aurora Health Care Urges All Wisconsin Residents to Take Vitamin D 2Health News:Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas 2Health News:Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas 3Health News:Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas 4Health News:BAPTIST HEALTH Uses Real-Time Clinical Surveillance from Thomson Reuters to Lower Costs and Improve Quality in the Pharmacy 2Health News:BAPTIST HEALTH Uses Real-Time Clinical Surveillance from Thomson Reuters to Lower Costs and Improve Quality in the Pharmacy 3Health News:Higher Chemo Drug Dose Prolongs Lives of Leukemia Patients 2
...ans for the Northeast have been announced by the H...is expected to be opened by 2015//. The five exis...d in Dundalk, Drogheda, Navan, Monaghan. and Cavan... Walsh at Monaghan General Hospital last year cons...
...Municipal Corporation’s (BMC) Health Committee had...d conducted health camps// Chamunda Nagar and Shya...on have been reported. Their report has concluded ...te survey conducted by an NGO, Bal Hakk Abhiyan (B...
...e July 15 issue of Clinical Infectious Diseases sa...s could be very useful// in the event of an influe...atins lower "bad" cholesterol levels in the blood ... cholesterol. Statins may further protect the hear...
...he medicos who had resorted to the strike against ...h Minister Anbumani Ramadoss today said that not p...as not a punishment. 'It is not a punitive action....elease the salaries, we will do so,' he told repor...
Other Medicine News:Health News:Children In Slums Of Mumbai Might be Suffering From Malnutrition 2Health News:Statins Could Play Important Role In Influenza Pandemic 2
(Date:12/2/2008)...RNewswire-USNewswire/ -- Researchers using functio... in the area of the brain,responsible for suppres... from,stress-related psychiatric disorders. Resul...nual meeting of the Radiological Society of North ... depression and other stress-related disorders,t...
(Date:12/2/2008)... 2 Horizon Therapeutics, Inc., a,...nounced that two pivotal,Phase 3 trials evaluatin...501,met all primary endpoints. HZT-501, a novel,...ining ibuprofen and famotidine, demonstrated a,st... of non-steroidal,anti-inflammatory drug (NSAID)-...
(Date:12/1/2008)... TargeGen has announced that an ora...ti-center, US-based clinical,trial of TG101348 in...duled at,the 2008 American Society of Hematology ...ion are as follows:, Title: A P... JAK2-Selective Inhibitor, ...
(Date:12/1/2008)...s still the best policy , , ROCHESTER, Min...from Mayo Clinic finds the use of the drug therapy...titis, an acute inflammation of the liver caused b... the study are published in the December issue of ... ). , , VIDEO ALERT: Additional audio and ...
Breaking Medicine Technology:Stress-Related Disorders Affect Brain's Processing of Memory 2Stress-Related Disorders Affect Brain's Processing of Memory 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 1Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 2Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 3Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 4Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 5Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 6Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 7Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 8Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 9Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 10Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 11Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 12Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 13Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 14Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 15Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 16Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 17Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 18Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 19Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 20Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 21Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 22Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 23Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 24Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 25Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 26Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 27Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 28Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 29Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 30Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 31Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 32Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 33Cadence Pharmaceuticals CEO Ted Schroeder to Present at Three Investment Conferences During the Month of May 2008 4998 1Cadence Pharmaceuticals CEO Ted Schroeder to Present at Three Investment Conferences During the Month of May 2008 4998 2ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing 1948 1ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing 1948 2ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing 1948 3ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing 1948 4Genetic Changes May Dictate Course of Acute Myeloid Leukemia 18089 1Genetic Changes May Dictate Course of Acute Myeloid Leukemia 18089 2Genetic Changes May Dictate Course of Acute Myeloid Leukemia 18089 3
...tudy evaluating a clinically relevant model of,nor...gent capable,of abrogating the cytotoxic effect of...d OPTISOME(tm) agent was generally well,tolerated ...ent,profile similar to conventional vincristine , ...EWSWIRE) --,Hana Biosciences (Nasdaq:HNAB), a biop...
..., NJ – June 4, 2007 – Genta,Incorporat...sults,from a Phase 2 clinical trial of its markete..., plus rituximab (Rituxan®;,Genentech/IDEC) an...ctory non-Hodgkin’s lymphoma (NHL). The data...can Society of Clinical,Oncology (ASCO) in Chicago...
Other Medicine Technology:Hana Biosciences Presents Data On Two Programs At the American,Society of Clinical Oncology Annual Meeting 2Hana Biosciences Presents Data On Two Programs At the American,Society of Clinical Oncology Annual Meeting 3Hana Biosciences Presents Data On Two Programs At the American,Society of Clinical Oncology Annual Meeting 4Hana Biosciences Presents Data On Two Programs At the American,Society of Clinical Oncology Annual Meeting 5Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 2Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 3Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 4Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 5
Non-sterile Silicone Tubing
Anodized aluminum. Durable and lightweight with built-in protection against rust. Security locks ensure against accidental opening. Silicone matting/V-strips and bumper guards hold instruments in pla
Diamond knife tray with silicone inserts to securely hold the diamond knife.
Size: 6 x 10 inches. Depth: 7 inches. Sterilizable plastic tray with silicone matting for supporting and protecting instruments.
Medicine Products: